Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug

References

• Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. Journal of Psychopharmacology 2005; 19(4)395–401
   PubMed Web of Science ®Google Scholar
• Bohets H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K. Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 2001; 1(5)367–383
   PubMedGoogle Scholar
• Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. American Journal of Respiratory and Critical Care Medicine 2005; 171(8)889–898
   PubMed Web of Science ®Google Scholar
• Cashman JR. Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochemical and Biophysical Research Communications 2005; 338(1)599–604
   PubMed Web of Science ®Google Scholar
• DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Molecular Pharmacology 2004; 65(3)744–752
   PubMed Web of Science ®Google Scholar
• De Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. British Journal of Pharmacology 2005; 145(2)166–177
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nature Genetics 2001; 29: 117–129
   PubMed Web of Science ®Google Scholar
• Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. Journal of Pharmacology and Experimental Therapeutics 2005; 313(3)943–951
   PubMed Web of Science ®Google Scholar
• Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clinical Pharmacokinetics 2003; 42(14)1243–1285
   PubMed Web of Science ®Google Scholar
• Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. The pharmacological basis of therapeutics9th. McGraw-Hill, New York, NY 1996; 860
   Google Scholar
• Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Molecular Pharmacology 2002; 62(1)65–74
   PubMed Web of Science ®Google Scholar
• Kaminska B, Wesolowska A, Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochimica Polonica 2005; 52(2)329–337
   PubMed Web of Science ®Google Scholar
• Kelly M, Kolb M, Bonniaud P, Gauldie J. A re-evaluation of fibrogenic cytokines in lung fibrosis. Current Pharmaceutical Design 2003; 9: 39–49
   PubMed Web of Science ®Google Scholar
• Kim DK, Bang YJ, Kim HT, Cho IS, Park MS, An YJ. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors. 2005, WO 2005/103028 A1
   Google Scholar
• Kim DK, Jang Y, Lee HS, Park HJ, Yoo J. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Journal of medicinal chemistry 2007; 50(13)3143–3147
   PubMed Web of Science ®Google Scholar
• Kim YW, Kim YK, Kim DK, Sheen YY. Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel ALK5 inhibitor. 2008, Xenobiotica (under revision)
   Google Scholar
• Kwan KC. Oral bioavailability and first-pass effects. Drug Metabolism and Disposition 1997; 25(12)1329–1336
   PubMed Web of Science ®Google Scholar
• Massagué J, Gomis RR. The logic of TGFb signaling. FEBS Letters 2006; 580(12)2811–2820
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000; 60(5)1123–1140
   PubMed Web of Science ®Google Scholar
• Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney International 2006; 70(7)1234–1243
   PubMed Web of Science ®Google Scholar
• Oft M, Heider KH, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Current Biology 1998; 8(23)1243–1252
   PubMed Web of Science ®Google Scholar
• Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Current Cancer Drug Targets 2006; 6(7)565–578
   PubMed Web of Science ®Google Scholar
• Siegel PM, Massagué J. Cytostatic and apoptotic action of TGF-β in homeostasis and cancer. Nature Reviews Cancer 2003; 3: 807–821
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis. World Journal of Gastroenterology 2007; 13(22)3056–3062
   PubMed Web of Science ®Google Scholar
• Wang JS, DeVane CL. Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacology Bulletin 2003; 37(1)10–29
   PubMedGoogle Scholar
• Washio T, Arisawa H, Kohsaka K, Yasuda H. Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biological and Pharmaceutical Bulletin 2001; 24(11)1263–1266
   PubMed Web of Science ®Google Scholar
• Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery 2004; 3(12)1011–1022
   PubMed Web of Science ®Google Scholar